Chief Executive Officer
Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with 30+ years of experience in drug discovery, translational medicine, and business leadership.
Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec, where he led a team of over 1,000 R&D personnel in research business enabling drug discovery and development for hundreds of pharmaceutical and biotech companies around the world. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca's global translational medicine portfolio. Dr. Ji started his industry career in the U.S where he served ONYX Pharmaceuticals and OSI Pharmaceuticals, respectively.
Dr. Ji obtained his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received Bachelor degree of Medicine in China
Dr. Ji is author of more than 50 peer-reviewed research articles and book chapters. In addition, he is a co-founder and vice chair of Sino Drug Discovery Association (SDDA).
Chief Scientific Officer
Dr. Curt Bradshaw, Chief Scientific Officer (CSO) of Sirius Therapeutics, is a highly-regarded pharmaceutical executive who has accumulated over 30 years of experience in drug and chemical development, including 11 years leading the development of siRNA therapeutics.
Dr. Bradshaw joined CovX Pharmaceuticals Inc as a vice president of research and development in September 2002. He later joined Traversa Therapeutics, Inc. as the chief scientific officer in December 2009. Later, he served as the president and the chief scientific officer at Solstice Biologics. In 2018, he founded Tallac Therapeutics, Inc. and had served as the chief scientific officer and a member of the board of directors until October 2019. From November 2019 to November 2020, he was the chief scientific officer of Arrowhead Pharmaceuticals, Inc. (a company listed on NASDAQ, ticker symbol: ARWR). He served as the chief scientific officer of NeuBase Therapeutics, Inc. (a company listed on NASDAQ, ticker symbol: NBSE) from December 2020 to June 2021.
Dr. Bradshaw obtained a Ph.D. degree in organic chemistry from Texas A&M University in the United States in April 1992.
Chief Medical Officer
Dr. Patrick Yue, Chief Medical Officer of Sirius Therapeutics, has extensive leadership experience in clinical development including the anti-coagulant therapeutic area.
Dr. Yue has extensive leadership experience in clinical development. He previously worked at Gilead Sciences, Inc. (a company listed on NASDAQ, ticker symbol: GILD). He was an executive director of clinical development at Portola Pharmaceuticals, Inc. from July 2016 to October 2020. Dr. Yue served as an executive director of clinical science at Global Blood Therapeutics, Inc. (later acquired by Pfizer Inc.) from October 2020 to February 2023. Prior to joining the Group, he was a senior vice president at Centessa Pharmaceuticals plc (a company listed on NASDAQ, ticker symbol: CNTA) and a director of ApcinteX Limited (a subsidiary of Centessa Pharmaceuticals plc) from February 2023 to June 2024.
Dr. Yue obtained a Bachelor of Science in biology and chemistry form California Institute of Technology in the United States in June 1995 and a Doctor of Medicine from the school of medicine of Washington University in the United States in May 1999. Dr. Yue also completed his medical internship and residency at Beth Israel Deaconess Medical Center in the United States from June 1999 to June 2002 and received specialty training in cardiovascular medicine at Stanford University School of Medicine from July 2002 to June 2005.
Dr. Yue has been licensed as a physician and surgeon by the Medical Board of California of the United States.
Chief Financial Officer
Hailei Lu, Chief Financial Officer, brings more than 15 years of expertise in capital market, mergers and acquisitions, business development and financial management. Prior to joining the Company, Mr. Lu held senior positions at several leading financial institutions and a pharmaceutical company, including Haisco Pharmaceutical Group Co., Ltd. (海思科醫藥集團股份有限公司)(a company listed on the Shenzhen Stock Exchange, stock code: 2653) from February 2024 to August 2025, the investment banking division at Goldman Sachs (Asia) L.L.C. from June 2015 to September 2023, the structured finance department at Crédit Agricole Corporate and Investment Bank from February 2011 to April 2014 and the audit department at Deloitte Touche Tohmatsu from January 2009 to January 2011.
Mr. Lu obtained a bachelor's degree in business administration from the Hong Kong University of Science and Technology in Hong Kong in December 2008 and a master's degree in business administration from the University of Chicago Booth School of Business in the United States in June 2016.
Chairman
David Wang, M.D., Ph.D., is a Partner and Senior Managing Director on OrbiMed Asia team, focused on Greater China.
Previously, he was a Managing Director at WI Harper Group, responsible for healthcare investments in China. He also previously served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was a co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. Wang was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine.
He received his M.D. from Peking University Medical School and his doctorate in Developmental Biology from the California Institute of Technology.
Board Director
Dr. Wei Li is the Founding Partner at Creacion Ventures.
Before founding Creacion Ventures, Dr. Li served as the management partner in 6 Dimensions Capital, the partner of Fidelity Biotechnology and Fidelity Growth Partners Asia, and the co-founder of Innovent.
Dr. Wei Li has successfully founded or involved in the founding of a series of biotechnology companies in China and overseas, including Innovent Biologics (stock code: 1801. HK), CStone Pharmaceuticals (stock code: 2616. HK), Ocumension Therapeutics (stock code: 1477. HK), and Dewpoint Therapeutics.
Dr. Wei Li holds a Ph.D. degree in Biochemistry from Harvard University and an MBA degree from the Northwestern University – Kellogg School of Management.
Board Director
Mr. Diyong Xu is the Principal at Orbimed U.S. and former investment banking analyst at Lazard Freres & Co.
Mr. Diyong Xu holds a Master of Science (M.S.) degree in Management Science and Engineering from Stanford University, a M.S. degree in Molecular and Cellular Biology from the Dartmouth Medical School, and a Bachelor of Science degree in Biology from the Zhejiang University in China.
Board Director
Mr. Kevin Yuan is the Chief Executive Officer at Shanghai Hankang Private Equity Management Co., Ltd.
Mr. Hong Yuanquan has more than 20 years of experience investing in China’s biopharmaceutical industry and has led the investment in over 40 early-stage biopharmaceutical companies, including some that already became industry leaders, such as InnoCare Pharma (9969. HK, 688428. SH), AkesoBio (9926. HK), Keymed Biosciences (2162. HK), Chipscreen Biosciences (688321. SH), Abbisko Therapeutics (2256. HK), and OPM Biosciences (688293. SH).
Mr. Kevin Yuan holds a Master degree in Management from Zhejiang University and an MBA degree from the China Europe International Business School (CEIBS).
Board Director
Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with 30+ years of experience in drug discovery, translational medicine, and business leadership.
Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec, where he led a team of over 1,000 R&D personnel in research business enabling drug discovery and development for hundreds of pharmaceutical and biotech companies around the world. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca's global translational medicine portfolio. Dr. Ji started his industry career in the U.S where he served ONYX Pharmaceuticals and OSI Pharmaceuticals, respectively.
Dr. Ji obtained his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received Bachelor degree of Medicine in China
Dr. Ji is author of more than 50 peer-reviewed research articles and book chapters. In addition, he is a co-founder and vice chair of Sino Drug Discovery Association (SDDA).
Independent Director
Dr. Douglas Fambrough was the Founder, President and Chief Executive Officer of Dicerna Pharmaceuticals (a company that was acquired by Novo Nordisk for US$3.3 billion).
Dr. Douglas Fambrough holds a Ph.D. degree in Genetics from the University of California, Berkley, and a Bachelor degree in Biology from Cornell University.
Our lead investors have been investing in the global healthcare industry for over 20 years. Their portfolios cover a broad array of therapeutic areas and companies at various stages, from start-ups to large multinational enterprises.
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
